Exploring the continuum: Medical information to effective clinical practice*. Paper I: The translation of knowledge into clinical practice

Journal of Evaluation in Clinical Practice

Volumn 12, Issue 1, 2006, Pages 49-62

  Genuis, Shelagh K ^a   Genuis, Stephen J ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b University of Alberta ^*  (Canada)

Author keywords

Clinical practice; Clinical practice guidelines; Diffusion of innovations; Doctor autonomy; Doctor role; Evidence based medicine; Hormone replacement therapy; Information use; Knowledge transfer; Medical research; Menopause

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CONSENSUS; EVIDENCE BASED MEDICINE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; KNOWLEDGE; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL RESEARCH; MENOPAUSE; PHYSICIAN ATTITUDE; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL;

BIOMEDICAL RESEARCH; DIFFUSION OF INNOVATION; DRUG INDUSTRY; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MENOPAUSE; PHYSICIAN'S PRACTICE PATTERNS; POSTMENOPAUSE; SOCIAL CHANGE;

EID: 32344442459     PISSN: 13561294     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2005.00608.x     Document Type: Article

References (88)

1. Angell M. (2000) Is academic medicine for sale? New England Journal of Medicine 342, 1516-1518.
2. Bekelman J.E., Li Y. & Gross C.P. (2003) Scope and impact of financial conflicts of interest in biomedical research: a systematic review. Journal of the American Medical Association 289, 454-465.
3. Bell S.E. (1987) Changing ideas: the medicalization of menopause. Social Science and Medicine 24, 535-542.
4. Berg M. (1997) Problems and promises of the protocol. Social Science and Medicine 44, 1081-1088.
5. Bhandari M., Busse J.W., Jackowski D., Montori V.M., Schunemann H., Sprague S., Mears D., Schemitsch E.H., Heels-Ansdell D. & Devereaux P.J. (2004) Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. Canadian Medical Association Journal 170, 477-480.
6. Bodenheimer T. (2000) Uneasy alliance - clinical investigators and the pharmaceutical industry. New England Journal of Medicine 342, 1539-1544.
7. Borbas C., Morris N., McLaughlin B., Asinger R. & Gobel F. (2000) The role of clinical opinion leaders in guideline implementation and quality improvement. Chest 118, 24S-32S.
8. Breslau E.S., Davis W.W., Doner L., Eisner E.J., Goodman N.R., Meissner H.I., Rimer B.K. & Rossouw J.E. (2003) The hormone therapy dilemma: women respond. Journal of the American Medical Women's Association 58, 33-43.
9. Brown J.B., Carroll J., Boon H. & Marmoreo J. (2002) Women's decision-making about their health care: views over the life cycle. Patient Education and Counseling 48, 225-231.
10. Cesario S., Morin K. & Santa-Donato A. (2002) Evaluating the level of evidence of qualitative research. Journal of Obstetric, Gynecologic, and Neonatal Nursing 31, 708-714.
11. Charlton B.G. (1999) Clinical research methods for the new millennium. Journal of Evaluation in Clinical Practice 5, 251-263.
12. Choudhry N.K., Stelfox H.T. & Detsky A.S. (2002) Relationships between authors of clinical practice guidelines and the pharmaceutical industry. Journal of the American Medical Association 287, 612-617.
13. Christiansen C. (2001) Hormone replacement therapy for the postmenopausal woman. Maturitas 38, S1-S5.
14. Chubin D. (1976) The conceptualization of scientific specialties. Sociological Quarterly 17, 448-476.
15. Coleman J.S., Katz E. & Menzel H. (1966) Medical Innovation: A Diffusion Study. The Bobbs-Merrill Company, Inc, Indianapolis, IN.
16. Davidoff F., DeAngelis C.D., Drazen J.M. et al. (2001) Sponsorship, authorship, and accountability. New England Journal of Medicine 345, 825-826.
17. Djulbegovic B., Lacevic M., Cantor A., Fields K.K., Bennett C.L., Adams J.R., Kuderer N.M. & Lyman G.H. (2000) The uncertainty principle and industry-sponsored research. Lancet 356, 635-638.
18. Farquahar J.W., Fortmann S.P., Flora J.A., Taylor C.B., Haskell W.L., Williams P.T., Maccoby N. & Wood P.D. (1990) Effects of community wide education on cardiovascular disease risk factors: the Stanford five-city project. Journal of the American Medical Association 264, 359-365.
19. Fendrick A.M., Hirth R.A. & Chernew M.E. (1996) Differences between generalist and specialist physicians regarding Helicobacter pylori and peptic ulcer disease. American Journal of Gastroenterology 91, 1544-1552.
20. Freeman A.C. & Sweeney K. (2001) Why general practitioners do not implement evidence: qualitative study. British Medical Journal 323, 1100-1102.
21. Gabbay J. & le May A. (2004) Evidence based guidelines or collectively constructed 'mindlines?' Ethnographic study of knowledge management in primary care. British Medical Journal 329, 1013-1020.
22. Genazzani A.R. & Gambacciani M. (2001) HRT in the third millennium. Maturitas 38, S49-S55.
23. Genuis S.K. (2004) Exploring the role of medical and consumer literature in the diffusion of information related to hormone therapy for menopausal women. Masters Thesis, University of Alberta.
24. Genuis S.J. & Genuis S.K. (2004) Resisting cookbook medicine. British Medical Journal 329, 179.
25. Granovetter M.S. (1973) The strength of weak ties. American Journal of Sociology 78, 1360-1380.
26. Granovetter M. (1982) The strength of weak ties: a network theory revisited. In Social Structure and Network Analysis (eds P. V. Marshden & N. N. Lin), pp. 105-130. Sage Publications, Beverly Hills.
27. Haines A. & Jones R. (1994) Implementing findings of research. British Medical Journal 308, 1488-1492.
28. Hampton J.R. (2003) Guidelines - for the obedience of fools and the guidance of wise men? Clinical Medicine 3, 279-284.
29. Haskell S.G., Richardson E.D. & Horwitz R.I. (1997) The effect of estrogen replacement therapy on cognitive function in women: a critical review of the literature. Journal of Clinical Epidemiology 50, 1249-1264.
30. Healy D. (2002) Conflicting interests in Toronto: anatomy of a controversy at the interface of academia and industry. Perspectives in Biology and Medicine 45, 250-263.
31. Herrington D.M. & Howard T.D. (2003) From presumed benefit to potential harm - hormone therapy and heart disease. New England Journal of Medicine 349, 519-521.
32. Hersh A.L., Stefanick M.L. & Stafford R.S. (2004) National use of postmenopausal hormone therapy: annual Trends and response to recent evidence. Journal of the American Medical Association 291, 47-53.
33. Hodis H.N., Mack W.J., Azen S.P. et al. (2003) Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. New England Journal of Medicine 349, 535-545.
34. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B. & Vittinghoff E. & the Heart and Estrogen/progestin Replacement Study Research Group (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Journal of the American Medical Association 280, 605-613.
35. Hunter M.S., O'Dea I. & Britten N. (1997) Decision-making and hormone replacement therapy: a qualitative analysis. Social Science and Medicine 45, 1541-1548.
36. Hurwitz B. (2004) How does evidence based guidance influence determinations of medical negligence? British Medical Journal 329, 1024-1028.
37. Julian D.G. (2003) What is right and what is wrong about evidence-based medicine? Journal of Cardiovascular Electrophysiology 14, S2-S5.
38. Kaplan B., Rabinerson D., Yogev Y., Bar-Hava I., Bar J. & Orvieto R. (2002) A survey of physician's attitude and approach to hormone replacement therapy during menopause. Clinical and Experimental Obstetrics and Gynecology 29, 31-33.
39. Kenemans P., van Unnik G.A., Mijatovic V. & van der Mooren M.J. (2001) Perspectives in hormone replacement therapy. Maturitas 38, S41-S48.
40. Kiernan V. (2003) Diffusion of news about research. Science Communication 25, 3-13.
41. Kondro W. & Sibbald B. (2004) Drug company experts advised staff to withhold data about SSRI use in children. Canadian Medical Association Journal 170, 783.
42. Kotaska A. (2004) Inappropriate use of randomised trials to evaluate complex phenomena: case study of vaginal breech delivery. British Medical Journal 329, 1039-1042.
43. Krimsky S. & Rothenberg L.S. (1998) Financial interest and its disclosure in scientific publications. Journal of the American Medical Association 280, 225-226.
44. Landrum B.J. (1998) Marketing innovations to nurses, part 1: how people adopt innovations. Journal of Wound, Ostomy and Continence Nursing 25, 194-199.
45. Lawton B., Rose S., McLeod D. & Dowell A. (2003) Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users. British Medical Journal 327, 845-846.
46. Lexchin J.R. (2005) Implications of pharmaceutical industry funding on clinical research. Annals of Pharmacotherapy 39, 194-197.
47. Lexchin J., Bero L.A., Djulbegovic B. & Clark O. (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. British Medical Journal 326, 1167-1170.
48. Lipman T. (2000) Power and influence in clinical effectiveness and evidence-based medicine. Family Practice 17, 557-563.
49. Lipman T. (2004) The doctor, his patient, and the computerized evidence-based guideline. Journal of Evaluation in Clinical Practice 10, 163-176.
50. Lockwood S. (2004) 'Evidence of me' in evidence based medicine? British Medical Journal 329, 1033-1035.
51. Lomas J., Enkin M., Hannah W.J., Vayda E. & Singer J. (1991) Opinion leaders vs. audit and feedback to implement practice guidelines. Journal of the American Medical Association 265, 2202-2207.
52. Love S.M. (2003) Dr Susan Love's Menopause and Hormone Book. Three Rivers Press, New York.
53. Majumdar S.R., Almasi E.A. & Stafford R.S. (2004) Promotion and prescribing of hormone therapy after report of harm by the women's health initiative. Journal of the American Medical Association 292, 1983-1988.
54. Marshall B. (1983) Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1, 1273-1275.
55. Marshall B.J. (2002a) The discovery that Helicobacter pylori, a spiral bacterium, caused peptic ulcer disease. In Helicobacter Pioneers: Firsthand Accounts from the Scientists Who Discovered Helicobacters (ed. B. Marshall), pp. 165-202. Blackwell, Victoria Australia.
56. Marshall B. (ed.) (2002b) Helicobacter Pioneers: Firsthand Accounts from the Scientists Who Discovered Helicobacters. Blackwell, Victoria Australia.
57. McCarthy M. (2000) Company sought to block paper's publication. Lancet 356, 1659.
58. Meyer V.F. (2001) The medicalization of menopause: critique and consequences. International Journal of Health Services 31, 769-792.
59. Michelson J. (2004) Critique of (im) pure reason: evidence-based medicine and common sense. Journal of Evaluation in Clinical Practice 10, 157-161.
60. Moynihan R. (2003a) The making of a disease: female sexual dysfunction. British Medical Journal 326, 45-47.
61. Moynihan R. (2003b) Who pays for the pizza? Redefining the relationship between doctors and drug companies. 1: entanglement. British Medical Journal 326, 1189-1192.
62. Nathan D.G. & Weatherall D.J. (1999) Academia and industry: lessons from the unfortunate events in Toronto. Lancet 353, 771-772.
63. Oudshoorn N. (1990) On the making of sex hormones: research materials and the production of knowledge. Social Studies of Science 20, 5-33.
64. Palmlund I. (1997a) The marketing of estrogens for menopausal and postmenopausal women. Journal of Psychosomatic Obstetrics and Gynecology 18, 158-164.
65. Palmlund I. (1997b) The social construction of menopause as risk. Journal of Psychosomatic Obstetrics and Gynecology 18, 87-94.
66. Pearson M., Barnes N., Thomas M., Tate H. & Simnett S. (2004) Evaluating the effectiveness of asthma treatment in real-life practice. Journal of Evaluation in Clinical Practice 10, 297-305.
67. Phillips D., Kanter E., Bednarczyk B. & Tastad P. (1991) Importance of the lay press in the transmission of medical knowledge to the scientific community. New England Journal of Medicine 325, 1180-1183.
68. Pitkin J. (2002) Compliance with estrogen replacement therapy: current issues. Climacteric 5, 12-19.
69. Porta M. (2004) Is there life after evidence-based medicine? Journal of Evaluation in Clinical Practice 10, 147-152.
70. Puska P., Koskela K., McAlister A., Mayranen H., Smolander A., Moisio S., Viri L., Korpelainen V. & Rogers E.M. (1986) Use of lay opinion leaders to promote the diffusion of health innovations in a community programme: lessons learned from the North Karelia Project. Bulletin of the World Health Organization 64, 437-446.
71. Relman A.S. (2001) Separating continuing medical education from pharmaceutical marketing. Journal of the American Medical Association 285, 2009-2012.
72. Rogers E.M. (1995) Diffusion of Innovations, 4th Edn. The Free Press, New York.
73. Rose G. (1985) Sick individuals and sick populations. International Journal of Epidemiology 14, 32-38.
74. Rossouw J.E., Anderson G.L., Prentice R.L. et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 288, 321-333.
75. Rossouw J.E., Finnegan L.P., Harlan W.R., Pinn V.W., Clifford C. & McGowan J.A. (1995) The evolution of the Women's Health Initiative: perspectives from the NIH. Journal of the American Medical Women's Association 50, 50-55.
76. Sackett D.L., Rosenberg W.M.C., Gray J.A.M., Haynes R.B. & Richardson W.S. (1996) Evidence based medicine: what it is and what it isn't. British Medical Journal 312, 71-72.
77. Sackett D.L., Straus S.E., Richardson W.S., Rosenberg W. & Haynes R.B. (2000) Evidence Based Medicine: How to Practice and Teach EBM, 2nd Edn. Churchill Livingstone, Edinburgh.
78. Seaman B. (2003) The Greatest Experiment Ever Performed on Women: Exploding the Estrogen Myth. Hyperion, New York.
79. Session D.R. & Jewelwicz R. (1993) Current concepts in estrogen replacement therapy in the menopause. Fertility and Sterility 59, 277-284.
80. Singer C. & Underwood E.A. (1962) A Short History of Medicine. Oxford University Press, New York.
81. Steer H.W. (2002) The discovery of Helicobacter pylori in England in the 1970s. In Helicobacter Pioneers: First-hand Accounts from the Scientists who Discovered Helicobacters (ed. B. Marshall), pp. 119-130. Blackwell, Victoria Australia.
82. Stephens C., Budge R.C. & Carryer J. (2002) What is this things called hormone replacement therapy? Discursive construction of medication in situated practice. Qualitative Health Research 12, 347-359.
83. Thompson W. (1995) Estrogen replacement therapy in practice: trends and issues. American Journal of Obstetrics and Gynecology 173, 990-993.
84. Topo P. (1997) Climacteric hormone therapy in medical and lay texts in Finland from 1955 to 1992. Social Science and Medicine 45, 751-760.
85. Wazana A. (2000) Physicians and the pharmaceutical industry: is a gift ever just a gift? Journal of the American Medical Association 283, 373-380.
86. Wilson R.A. (1966) Feminine Forever. M. Evans and Company, New York.
87. Winterich J.A. & Umberson D. (1999) How women experience menopause: the importance of social context. Journal of Women and Aging 11, 57-73.
88. Yaffe K., Sawaya G., Lieberburg I. & Grady D. (1998) Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. Journal of the American Medical Association 279, 688-695.